# SLM + Axitinib for Clear Cell RCC

> **NCT02535533** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mohammed Milhem** · enrollment: 45 (actual)

## Conditions studied

- Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

## Interventions

- **DRUG:** Selenomethionine (SLM)
- **DRUG:** Axitinib
- **DRUG:** Selenomethionine (SLM)
- **DRUG:** Axitinib
- **DRUG:** Selenomethionine (SLM)

## Key facts

- **NCT ID:** NCT02535533
- **Lead sponsor:** Mohammed Milhem
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2023-08-22
- **Final completion:** 2025-04-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- Pfizer

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535533, "SLM + Axitinib for Clear Cell RCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02535533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*